Gilead Sciences, Inc.

NasdaqGS:GILD

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 133.87 B

Share Price

USD 107.62

Avg Daily Volume

9,624,542

Change (1 day)

1.59%

Change (1 year)

55.27%

Change (YTD)

16.51%

Gilead Sciences, Inc. Total Liabilities for the year ending December 31, 2024: USD 39.75 B

Gilead Sciences, Inc. Total Liabilities is USD 39.75 B for the year ending December 31, 2024, a 0.95% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Gilead Sciences, Inc. Total Liabilities for the year ending December 31, 2023 was USD 39.38 B, a -6.16% change year over year.
Gilead Sciences, Inc. Total Liabilities for the year ending December 31, 2022 was USD 41.96 B, a -10.51% change year over year.
Gilead Sciences, Inc. Total Liabilities for the year ending December 31, 2021 was USD 46.89 B, a -6.57% change year over year.
Gilead Sciences, Inc. Total Liabilities for the year ending December 31, 2020 was USD 50.19 B, a 28.76% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

NasdaqGS: GILD

Gilead Sciences, Inc.

CEO	Mr. Daniel P. O'Day
IPO Date	Jan. 22, 1992
Location	United States
Headquarters	333 Lakeside Drive
Employees	17,600
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.